Nevro
A global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain.
Launch date
Employees
Market cap
CAD259m
Enterprise valuation
CAD216m (Public information from Sep 2024)
Share price
$5.82 NVRO
Redwood City California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 362m | 387m | 406m | 425m | 403m | 412m | 434m |
% growth | (7 %) | 7 % | 5 % | 5 % | (5 %) | 2 % | 5 % |
EBITDA | (62.9m) | (70.9m) | (204m) | (74.2m) | (19.9m) | (11.4m) | 6.1m |
% EBITDA margin | (17 %) | (18 %) | (50 %) | (17 %) | (5 %) | (3 %) | 1 % |
Profit | (83.1m) | (131m) | 3.0m | (92.2m) | (101m) | (96.9m) | (79.8m) |
% profit margin | (23 %) | (34 %) | 1 % | (22 %) | (25 %) | (24 %) | (18 %) |
EV / revenue | 15.7x | 6.8x | 3.0x | 1.6x | 0.4x | 0.5x | 0.5x |
EV / EBITDA | -90.4x | -36.9x | -6.0x | -9.0x | -8.8x | -18.1x | 33.3x |
R&D budget | 45.6m | 47.7m | 53.1m | 54.4m | - | - | - |
R&D % of revenue | 13 % | 12 % | 13 % | 13 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$5.5m | Series A | ||
$21.8m | Series A | ||
£58.0m | Series B | ||
$48.0m | Series C | ||
$50.0m | Debt | ||
N/A | N/A | IPO | |
N/A | $173m | Post IPO Debt | |
* | N/A | $200m | Post IPO Convertible |
Total Funding | CAD207m |